Efficacy and Tolerance of URGO AWC_008 and URGO AWC_022 Dressings (EXPANSION)

NCT ID: NCT05772507

Last Updated: 2023-09-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 85 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-22
• Study Completion Date: 2024-10-31

Brief Summary

Evaluation of the efficacy (wound epithelialization and time to closure) and tolerance (emergence and nature of adverse event) of the new URGO AWC_008 and URGO AWC_022 dressings in local management of acute and chronic wounds at risk of local infection or with clinical signs of local infection

Detailed Description

prospective multicenter, non comparative clinical investigation

This is a prospective multicenter, non comparative open-label, clinical investigation conducted in patients with acute and chronic wounds at risk of local infection or with clinical signs of local infection.

This study is carried out in France and Spain in around 30 investigator sites. A total of 85 patients meeting the eligibility criteria will be included. The patients will be followed for 4 weeks and a total of 5 clinical evaluations will be carried out by the investigating centers.

A planimetric survey of the studied wounds is carried out during the initial assessment of the wound (Day 0) and at each assessment provided for in the protocol (Week 1, Week 2, Week 3 and Week 4).

Conditions

Diabetic Foot Ulcer; Venous Leg Ulcer; Pressure Ulcer; Wound Infection; Acute Wounds

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

medical device under investigation

URGO AWC\_008 or URGO AWC\_022 dressing. These 2 dressings are similar and only the adhesive constitutes a difference. The choice of study dressing will be left to the discretion of the investigator during the treatment of the patient, depending on the nature of the wound and the condition of the peri-wound skin.

Group Type: EXPERIMENTAL

URGO AWC_008 dressing or URGO AWC_022 dressing

Intervention Type: DEVICE

local management of acute or chronic wounds

Interventions

URGO AWC_008 dressing or URGO AWC_022 dressing

local management of acute or chronic wounds

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

Related to all wounds :

• Adult patient having given free, informed and written consent
• Patient affiliated to a social security insurance scheme (applicable For France),
• Inpatient or outpatient who can be followed by the same investigative team throughout the investigation,
• Acute wound (burn, traumatic wound, unstitched surgical wound) or chronic wound (leg ulcer, pressure ulcer, diabetic foot ulcer),
• Wound whose surface can be covered by a single dressing,
• Wound at least 3 cm from any edge of another wound.

Related to acute wounds, leg ulcer, pressure ulcer:

Patient whose studied wound presents a risk of local infection (based on modified W.A.R. score ≥ 3 points) or with at least 3 of the following clinical signs:

• Pain (spontaneous, pressure pain or increased pain),
• Peri-wound erythema,
• Oedema, induration or swelling,
• Odour (increase, change),
• Exudate (colour modification or increase of exudate),
• Local warmth,
• Hypergranulation,
• Bleeding, friable granulation tissue,
• Stagnant healing/wound deterioration.

Related to diabetic foot ulcer :

Patient whose studied wound presents a risk of local infection (based on modified W.A.R. score ≥ 3 points) or with at least 2 of the following clinical signs:

• Pain (spontaneous, pressure pain or increased pain),
• Peri-wound erythema between 0.5-2.0 cm around the wound,
• Oedema, induration or swelling,
• Odour (increase, change),
• Exudate (colour modification or increase of exudate),
• Local warmth,
• Hypergranulation,
• Bleeding, friable granulation tissue,
• Stagnant healing/wound deterioration,

Exclusion Criteria

• Patient with a wound for which treatment in a hyperbaric chamber is planned within 4 weeks following inclusion,
• Patient with a serious general condition, that could lead to withdrawal from the trial before four weeks of treatment,
• Patient who has experienced an acute ischaemic event (acute myocardial infarction or stroke) during the 3 months prior to inclusion in the investigation,
• Patient with a systemic infection
• Wound totally or partially covered on its surface with a black plaque of necrosis,
• Cancerous wound

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Laboratoires URGO

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

URGO

Dijon, , France

Site Status: RECRUITING

Countries

France

Facility Contacts

Clemence TUMBA, PharmD

Role: primary

c.tumba@fr.urgo.com

+33 3 80 44 74 09

Olivier TACCA, PhD

Role: backup

o.tacca@fr.urgo.com

+33 3 80 44 74 22

Other Identifiers

IDRCB no.: 2022-A00862-41

Identifier Type: -

Identifier Source: org_study_id